KRAS and melanoma: Binimetinib is a MEK 1/2 inhibitor that has shown clinical therapeutic efficacy against KRAS-mutated cancers such as acute myeloid leukemia, colorectal cancer, melanoma, and NSCLC, especially when in combination with other drugs [62,63,64].